Plant Name: Helichrysum subulifolium
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ACHE; | |
| RECQL; ALOX12; HSD17B10; NOX4; ALOX15; POLB; APEX1; | |
| CDK2; ROCK1; GSK3B; CAMK2A; CAMK1D; RPS6KA3; JAK3; CAMKK2; PRKACA; PRKCQ; PDGFRA; GRK5; SGK2; RET; STK3; CSNK1A1; SIK2; ROCK2; TBK1; IKBKE; DYRK1B; FGFR1; FLT1; PIM1; GSK3A; TYRO3; ALK; CDK6; CLK2; ROS1; JAK2; MAP4K4; BTK; LRRK2; PTK2; LTK; TAOK1; MAPK10; HCK; MARK4; MARK3; ACVR1; CDK8; DYRK1A; MAP3K10; PRKX; TNK2; MELK; | |
| MAPT; HTT; | |
| XDH; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Kinase | CLK2 | Dual specificity protein kinase CLK2 | P49760 | CHEMBL4225 |
| Protein Kinase | ROS1 | Proto-oncogene tyrosine-protein kinase ROS | P08922 | CHEMBL5568 |
| Protein Kinase | JAK2 | Tyrosine-protein kinase JAK2 | O60674 | CHEMBL2971 |
| Protein Kinase | MAP4K4 | Mitogen-activated protein kinase kinase kinase kinase 4 | O95819 | CHEMBL6166 |
| Protein Kinase | BTK | Tyrosine-protein kinase BTK | Q06187 | CHEMBL5251 |
| Protein Kinase | LRRK2 | Leucine-rich repeat serine/threonine-protein kinase 2 | Q5S007 | CHEMBL1075104 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | LTK | Leukocyte tyrosine kinase receptor | P29376 | CHEMBL5627 |
| Protein Kinase | TAOK1 | Serine/threonine-protein kinase TAO1 | Q7L7X3 | CHEMBL5261 |
| Protein Kinase | MAPK10 | c-Jun N-terminal kinase 3 | P53779 | CHEMBL2637 |
| Protein Kinase | HCK | Tyrosine-protein kinase HCK | P08631 | CHEMBL3234 |
| Protein Kinase | MARK4 | MAP/microtubule affinity-regulating kinase 4 | Q96L34 | CHEMBL5754 |
| Protein Kinase | MARK3 | Serine/threonine-protein kinase c-TAK1 | P27448 | CHEMBL5600 |
| Protein Kinase | ACVR1 | Activin receptor type-1 | Q04771 | CHEMBL5903 |
| Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
| Protein Kinase | DYRK1A | Dual-specificity tyrosine-phosphorylation regulated kinase 1A | Q13627 | CHEMBL2292 |
| Protein Kinase | MAP3K10 | Mitogen-activated protein kinase kinase kinase 10 | Q02779 | CHEMBL2873 |
| Protein Kinase | PRKX | Serine/threonine-protein kinase PRKX | P51817 | CHEMBL5818 |
| Protein Kinase | TNK2 | Tyrosine kinase non-receptor protein 2 | Q07912 | CHEMBL4599 |
| Protein Kinase | MELK | Maternal embryonic leucine zipper kinase | Q14680 | CHEMBL4578 |
| Protein Kinase | CDK2 | Cyclin-dependent kinase 2 | P24941 | CHEMBL301 |
| Protein Kinase | ROCK1 | Rho-associated protein kinase 1 | Q13464 | CHEMBL3231 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | CAMK2A | CaM kinase II alpha | Q9UQM7 | CHEMBL4147 |
| Protein Kinase | CAMK1D | CaM kinase I delta | Q8IU85 | CHEMBL5073 |
| Protein Kinase | RPS6KA3 | Ribosomal protein S6 kinase alpha 3 | P51812 | CHEMBL2345 |
| Protein Kinase | JAK3 | Tyrosine-protein kinase JAK3 | P52333 | CHEMBL2148 |
| Protein Kinase | CAMKK2 | CaM-kinase kinase beta | Q96RR4 | CHEMBL5284 |
| Protein Kinase | PRKACA | cAMP-dependent protein kinase alpha-catalytic subunit | P17612 | CHEMBL4101 |
| Protein Kinase | PRKCQ | Protein kinase C theta | Q04759 | CHEMBL3920 |
| Protein Kinase | PDGFRA | Platelet-derived growth factor receptor alpha | P16234 | CHEMBL2007 |
| Protein Kinase | GRK5 | G protein-coupled receptor kinase 5 | P34947 | CHEMBL5678 |
| Protein Kinase | SGK2 | Serine/threonine-protein kinase Sgk2 | Q9HBY8 | CHEMBL5794 |
| Protein Kinase | RET | Tyrosine-protein kinase receptor RET | P07949 | CHEMBL2041 |
| Protein Kinase | STK3 | Serine/threonine-protein kinase MST2 | Q13188 | CHEMBL4708 |
| Protein Kinase | CSNK1A1 | Casein kinase I alpha | P48729 | CHEMBL2793 |
| Protein Kinase | SIK2 | Serine/threonine-protein kinase SIK2 | Q9H0K1 | CHEMBL5699 |
| Protein Kinase | ROCK2 | Rho-associated protein kinase 2 | O75116 | CHEMBL2973 |
| Protein Kinase | TBK1 | Serine/threonine-protein kinase TBK1 | Q9UHD2 | CHEMBL5408 |
| Protein Kinase | IKBKE | Inhibitor of nuclear factor kappa B kinase epsilon subunit | Q14164 | CHEMBL3529 |
| Protein Kinase | DYRK1B | Dual specificity tyrosine-phosphorylation-regulated kinase 1B | Q9Y463 | CHEMBL5543 |
| Protein Kinase | FGFR1 | Fibroblast growth factor receptor 1 | P11362 | CHEMBL3650 |
| Protein Kinase | FLT1 | Vascular endothelial growth factor receptor 1 | P17948 | CHEMBL1868 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | GSK3A | Glycogen synthase kinase-3 alpha | P49840 | CHEMBL2850 |
| Protein Kinase | TYRO3 | Tyrosine-protein kinase receptor TYRO3 | Q06418 | CHEMBL5314 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004715; non-membrane spanning protein tyrosine kinase activity | 2.659E-12 | 6.812E-10 | BTK, DYRK1A, HCK, JAK2, JAK3, MELK, PTK2, TNK2 |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 4.325E-11 | 8.885E-09 | ACVR1, ALOX12, CAMK1D, GRK5, GSK3B, HCK, HTT, JAK2, JAK3, LRRK2, LTK, MAP4K4, PIM1, PRKCQ, PTK2, ROCK1, RPS6KA3, TYRO3 |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 9.818E-11 | 1.926E-08 | BTK, HCK, JAK2, JAK3, PTK2, ROS1, TNK2 |
| CC | GO:0044464; cell part | GO:0031234; extrinsic component of cytoplasmic side of plasma membrane | 2.168E-09 | 3.576E-07 | ALOX15, BTK, HCK, JAK2, JAK3, PTK2, TNK2 |
| BP | GO:0065007; biological regulation | GO:0065008; regulation of biological quality | 2.016E-08 | 2.966E-06 | ACHE, ALOX12, ALOX15, APEX1, BTK, CAMK2A, CDK6, CSNK1A1, FGFR1, GSK3A, GSK3B, HCK, HTT, IKBKE, JAK2, JAK3, LRRK2, MAP4K4, MAPT, NOX4, PDGFRA, POLB, PRKACA, PRKCQ, PTK2, RET, STK3, TYRO3, XDH |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 2.355E-08 | 3.396E-06 | ALOX12, ALOX15, BTK, CAMK2A, CAMKK2, CDK2, CDK6, CSNK1A1, FGFR1, GRK5, GSK3A, GSK3B, HCK, HTT, IKBKE, JAK2, JAK3, LRRK2, MAPK10, MAPT, MARK3, MARK4, PIM1, PRKACA, PRKCQ, PTK2, RET, ROCK1, ROCK2, RPS6KA3, SGK2, STK3, TAOK1, TBK1, XDH |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 2.736E-45 | 6.620E-42 | ACVR1, ALK, BTK, CAMK1D, CAMK2A, CAMKK2, CDK2, CDK6, CDK8, CLK2, CSNK1A1, DYRK1A, DYRK1B, FGFR1, FLT1, GRK5, GSK3A, GSK3B, HCK, IKBKE, JAK2, JAK3, LRRK2, LTK, MAP3K10, MAP4K4, MAPK10, MARK3, MARK4, MELK, PDGFRA, PIM1, PRKACA, PRKCQ, PRKX, PTK2, RECQL, RET, ROCK1, ROCK2, ROS1, RPS6KA3, SGK2, SIK2, STK3, TAOK1, TBK1, TNK2, TYRO3 |
| BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 8.285E-08 | 1.128E-05 | ACVR1, ALOX12, CAMK1D, FGFR1, FLT1, JAK2, NOX4, PDGFRA, PTK2, RET, ROCK2 |
| BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 1.733E-06 | 2.073E-04 | FGFR1, FLT1, JAK2, PDGFRA, PTK2 |
| BP | GO:0032502; developmental process | GO:0022603; regulation of anatomical structure morphogenesis | 1.817E-06 | 2.162E-04 | ACVR1, ALOX12, CSNK1A1, FGFR1, FLT1, HCK, LRRK2, MAPT, PIM1, PTK2, RET, ROCK1, ROCK2, XDH |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 2.101E-06 | 2.473E-04 | ALOX12, CDK2, CDK6, FGFR1, FLT1, GRK5, HCK, JAK2, JAK3, PDGFRA, PIM1, PRKCQ, PTK2 |
| BP | GO:0009987; cellular process | GO:0071310; cellular response to organic substance | 2.664E-06 | 3.037E-04 | ACVR1, ALOX15, APEX1, BTK, CDK6, FLT1, GSK3A, GSK3B, LRRK2, LTK, NOX4, PRKACA, RET, ROCK2, SIK2 |
| MF | GO:0005488; binding | GO:0034452; dynactin binding | 4.389E-06 | 4.827E-04 | GSK3B, HTT, MAPT |
| CC | GO:0032991; macromolecular complex | GO:0030877; beta-catenin destruction complex | 4.389E-06 | 4.827E-04 | CSNK1A1, GSK3A, GSK3B |
| BP | GO:0008152; metabolic process | GO:0010468; regulation of gene expression | 4.499E-06 | 4.900E-04 | ACVR1, ALK, APEX1, BTK, CAMK1D, CAMK2A, CAMKK2, CDK2, CDK6, CDK8, CLK2, DYRK1A, DYRK1B, FGFR1, GSK3A, GSK3B, HCK, JAK2, LRRK2, MAP3K10, MAPK10, MAPT, PIM1, PRKCQ, RET, ROCK2, ROS1, RPS6KA3, STK3, TBK1, XDH |
| BP | GO:0009987; cellular process | GO:0097194; execution phase of apoptosis | 5.362E-06 | 5.668E-04 | PRKCQ, PTK2, ROCK1, TAOK1 |
| BP | GO:0050896; response to stimulus | GO:0006954; inflammatory response | 6.357E-06 | 6.623E-04 | ACVR1, ALOX15, CAMK1D, HCK, JAK3, NOX4, POLB, PRKCQ, TBK1 |
| MF | GO:0003824; catalytic activity | GO:0050321; tau-protein kinase activity | 7.575E-06 | 7.817E-04 | GSK3A, GSK3B, MARK4 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 9.172E-06 | 9.120E-04 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 9.172E-06 | 9.120E-04 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 9.172E-06 | 9.120E-04 | ALOX12, ALOX15 |
| MF | GO:0098772; molecular function regulator | GO:0005088; Ras guanyl-nucleotide exchange factor activity | 1.048E-05 | 1.028E-03 | CAMK2A, FGFR1, JAK2, JAK3, PDGFRA, PTK2, RET |
| CC | GO:0044464; cell part | GO:0042995; cell projection | 1.277E-05 | 1.236E-03 | CAMK2A, CAMKK2, CDK6, CSNK1A1, GSK3A, HCK, HTT, LRRK2, MAPK10, MAPT, MARK4, PRKACA, PTK2, RET, ROCK1 |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 1.960E-05 | 1.832E-03 | APEX1, BTK, CAMKK2, CDK2, PDGFRA |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 2.746E-05 | 2.441E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 2.746E-05 | 2.441E-03 | ALOX12, ALOX15 |
| BP | GO:0009987; cellular process | GO:0007346; regulation of mitotic cell cycle | 2.805E-05 | 2.483E-03 | APEX1, CDK2, CDK6, CDK8, FGFR1, MAP4K4, PIM1, PRKACA, STK3, TAOK1 |
| BP | GO:0032501; multicellular organismal process | GO:0051240; positive regulation of multicellular organismal process | 4.271E-05 | 3.591E-03 | ACVR1, ALOX12, BTK, CAMK1D, FGFR1, FLT1, GSK3A, JAK2, LTK, MAPT, PIM1, PRKCQ, RET, ROCK2, TBK1 |
| BP | GO:0009987; cellular process | GO:0009968; negative regulation of signal transduction | 4.804E-05 | 3.992E-03 | ACVR1, CSNK1A1, DYRK1A, GSK3A, GSK3B, HTT, LRRK2, MARK3, PDGFRA, PRKCQ, STK3, TYRO3, XDH |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 6.917E-05 | 5.477E-03 | FLT1, PTK2, ROCK1, ROCK2 |
| BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 7.526E-05 | 5.874E-03 | ALK, LRRK2, MAP3K10, MAPK10, TAOK1 |
| BP | GO:0032502; developmental process | GO:0051093; negative regulation of developmental process | 8.217E-05 | 6.322E-03 | CDK6, GSK3A, GSK3B, JAK3, MAP4K4, MAPT, PTK2, ROCK1, ROCK2, STK3, XDH |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 9.118E-05 | 6.708E-03 | ALOX12, ALOX15 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.004E-04 | 7.252E-03 | FGFR1, NOX4, PDGFRA, PTK2, STK3 |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 1.036E-04 | 7.423E-03 | FLT1, PDGFRA, PTK2 |
| BP | GO:0008152; metabolic process | GO:0032436; positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 1.096E-04 | 7.824E-03 | CSNK1A1, GSK3A, GSK3B, LRRK2 |
| BP | GO:0009987; cellular process | GO:2001236; regulation of extrinsic apoptotic signaling pathway | 1.101E-04 | 7.835E-03 | ACVR1, FGFR1, HTT, RET, STK3 |
| BP | GO:0050896; response to stimulus | GO:0032101; regulation of response to external stimulus | 1.198E-04 | 8.440E-03 | ALOX12, BTK, CAMK1D, FGFR1, HCK, JAK2, PDGFRA, PRKCQ, TBK1, TYRO3 |
| BP | GO:0009987; cellular process | GO:0010543; regulation of platelet activation | 1.261E-04 | 8.855E-03 | ALOX12, PDGFRA, PRKCQ |
| CC | GO:0043226; organelle | GO:0016607; nuclear speck | 1.274E-04 | 8.917E-03 | APEX1, CLK2, CSNK1A1, DYRK1A, GRK5, MAPT, PRKACA |
| CC | Unclassified; | GO:0120025; plasma membrane bounded cell projection | 1.319E-04 | 9.206E-03 | CAMK2A, CDK6, CSNK1A1, GSK3A, HTT, LRRK2, MAPK10, MAPT, MARK4, PRKACA, PTK2, RET, ROCK1 |
| BP | GO:0065007; biological regulation | GO:0010863; positive regulation of phospholipase C activity | 1.384E-04 | 9.445E-03 | FGFR1, FLT1, PDGFRA |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 3.059E-20 | 1.514E-17 | CAMK1D, CAMK2A, CAMKK2, CDK2, CSNK1A1, DYRK1A, GSK3B, IKBKE, LRRK2, MAP3K10, PRKACA, PRKCQ, PRKX, RPS6KA3, SGK2, TBK1 |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 3.398E-14 | 1.138E-11 | ACVR1, CAMK1D, CAMK2A, CAMKK2, DYRK1A, GSK3A, GSK3B, LRRK2, MAP3K10, TBK1 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 1.694E-10 | 2.508E-08 | GSK3B; HCK; GSK3A; ROCK1; GRK5; ROCK2; PRKACA; JAK2; JAK3; PTK2 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.955E-08 | 9.647E-07 | RET; MAPK10; PDGFRA; GSK3B; CDK6; ROCK1; ROCK2; CDK2; PRKACA; PTK2; FGFR1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 6.153E-09 | 4.553E-07 | GSK3B; TBK1; CDK6; CDK2; PRKCQ; JAK2; JAK3; IKBKE |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 5.450E-08 | 1.650E-06 | PDGFRA; GSK3B; CDK6; FLT1; CDK2; JAK2; SGK2; JAK3; PTK2; FGFR1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 5.574E-08 | 1.650E-06 | MAPK10; PDGFRA; RPS6KA3; TAOK1; MAPT; PRKACA; MAP4K4; FGFR1; STK3 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 2.113E-06 | 5.212E-05 | MAPK10; PDGFRA; GSK3B; FLT1; ROCK1; ROCK2; PTK2 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 3.809E-06 | 8.054E-05 | MAPK10; GSK3B; ROCK2; CSNK1A1; CAMK2A; PRKACA |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 7.048E-06 | 1.304E-04 | CAMK1D; ROCK1; ROCK2; CAMK2A; PRKACA; CAMKK2 |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.035E-05 | 1.701E-04 | MAPK10; CAMK2A; PRKCQ; ALOX12; PRKACA |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.924E-05 | 3.934E-04 | ROCK1; ROCK2; CAMK2A; PRKACA; PTK2; FGFR1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 2.844E-05 | 3.934E-04 | MAPK10; GSK3B; TBK1; CDK2; PRKACA; JAK3 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 5.457E-05 | 5.769E-04 | MAPK10; PDGFRA; TBK1; FLT1; PRKACA; FGFR1 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 3.911E-05 | 4.824E-04 | MAPK10; GSK3B; GSK3A; CAMK2A; PRKACA |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 7.056E-05 | 6.527E-04 | MAPK10; TBK1; CDK6; CDK2; IKBKE |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 6.184E-05 | 6.102E-04 | ACVR1; GSK3B; JAK2; JAK3; FGFR1 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 5.415E-05 | 5.769E-04 | MAPK10; PRKCQ; JAK2; CAMKK2 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.655E-04 | 1.289E-03 | MAPK10; GSK3B; TBK1; JAK2; IKBKE |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.383E-04 | 1.137E-03 | PDGFRA; GSK3B; CDK2; FGFR1 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.267E-04 | 1.103E-03 | MAPK10; GSK3B; CAMK2A; PTK2 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 2.006E-04 | 1.485E-03 | MAPK10; RPS6KA3; CDK2; PRKACA |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 3.002E-04 | 1.941E-03 | MAPK10; ROCK1; ROCK2; CAMK2A; PRKACA |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 3.233E-04 | 1.994E-03 | ACHE; CAMK2A; PRKACA; JAK2 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 2.143E-04 | 1.510E-03 | MAPK10; TBK1; CDK2; JAK2; IKBKE |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 3.442E-04 | 2.038E-03 | POLB; CDK6; CDK2; PRKACA; JAK3 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 3.016E-04 | 1.941E-03 | MAPK10; GSK3B; RPS6KA3; PRKCQ |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 4.190E-04 | 2.219E-03 | PDGFRA; ROCK1; ROCK2; PTK2; FGFR1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 4.348E-04 | 2.219E-03 | MAPK10; GSK3B; RPS6KA3; CAMK2A |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 4.629E-04 | 2.279E-03 | ROCK1; ROCK2; BTK; PRKACA |
| hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 4.348E-04 | 2.219E-03 | ROCK1; ROCK2; PRKCQ; PRKACA |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 4.774E-04 | 2.279E-03 | RPS6KA3; CDK2; CAMK2A; PRKACA |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 6.409E-04 | 2.874E-03 | MAPK10; GSK3B; TBK1; IKBKE |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 9.749E-04 | 3.911E-03 | POLB; PDGFRA; GSK3B; PRKACA; JAK3 |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 5.387E-04 | 2.492E-03 | GSK3B; ROCK1; ROCK2; PTK2 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 9.354E-04 | 3.911E-03 | PDGFRA; CDK6; CAMK2A |
| hsa04340 | Hedgehog signaling pathway_Homo sapiens_hsa04340 | 4.331E-04 | 2.219E-03 | GSK3B; CSNK1A1; PRKACA |
| hsa04925 | Aldosterone synthesis and secretion_Homo sapiens_hsa04925 | 1.767E-03 | 6.227E-03 | CAMK1D; CAMK2A; PRKACA |
| hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 9.778E-04 | 3.911E-03 | RPS6KA3; CAMK2A; PRKACA |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 3.311E-03 | 1.021E-02 | MAPK10; PIM1; JAK2 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.209E-03 | 4.472E-03 | PDGFRA; CDK6; FGFR1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.022E-03 | 3.979E-03 | RET; PDGFRA; FGFR1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.259E-03 | 4.543E-03 | MAPK10; GSK3B; JAK2 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 2.464E-03 | 8.104E-03 | MAPK10; CAMK2A; PRKACA |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 9.354E-04 | 3.911E-03 | MAPK10; ROCK1; ROCK2 |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 3.219E-03 | 1.021E-02 | GSK3B; CAMK2A; PRKACA |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 3.311E-03 | 1.021E-02 | CAMK2A; SIK2; PRKACA |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 2.098E-03 | 7.055E-03 | CDK6; CDK2; PTK2 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 3.793E-03 | 1.146E-02 | MAPK10; TBK1; IKBKE |
| hsa04622 | RIG-I-like receptor signaling pathway_Homo sapiens_hsa04622 | 1.160E-03 | 4.402E-03 | MAPK10; TBK1; IKBKE |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 2.098E-03 | 7.055E-03 | MAPK10; ROCK1; ROCK2 |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 7.161E-03 | 1.859E-02 | RET; PDGFRA; FLT1; GRK5 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.425E-03 | 1.284E-02 | ALOX15; ALOX12; PRKACA |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 5.118E-03 | 1.457E-02 | ROCK1; ROCK2; PTK2 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.363E-03 | 1.470E-02 | MAPK10; ROCK1; ROCK2 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.007E-02 | 2.527E-02 | MAPK10; GSK3B; GSK3A |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 7.125E-03 | 1.859E-02 | MAPK10; CDK2; SGK2 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.144E-02 | 2.743E-02 | PDGFRA; CDK6; ROCK1; PIM1 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.138E-02 | 2.743E-02 | PIM1; JAK2; JAK3 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 5.873E-03 | 1.580E-02 | GSK3B; CDK6; CDK2 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 8.041E-03 | 2.052E-02 | MAPK10; GSK3B; PRKACA |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.342E-02 | 3.103E-02 | GSK3B; MAPT; HSD17B10 |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 1.612E-02 | 3.390E-02 | PDGFRA; CAMK2A; PRKACA |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.565E-02 | 3.357E-02 | MAPK10; CAMK2A; JAK2 |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 2.442E-02 | 4.694E-02 | PDGFRA; FLT1; FGFR1 |
| hsa04350 | TGF-beta signaling pathway_Homo sapiens_hsa04350 | 2.555E-02 | 4.848E-02 | ACVR1; ROCK1 |
| hsa04911 | Insulin secretion_Homo sapiens_hsa04911 | 2.612E-02 | 4.893E-02 | CAMK2A; PRKACA |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.966E-02 | 3.880E-02 | GSK3B; BTK |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 1.720E-02 | 3.488E-02 | MAPK10; BTK |
| hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 2.017E-02 | 3.928E-02 | CAMK2A; PRKACA |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.444E-02 | 3.239E-02 | MAPK10; GSK3B |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.626E-02 | 3.390E-02 | MAPK10; CDK6 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.190E-02 | 2.795E-02 | ALK; CDK6 |
| hsa05031 | Amphetamine addiction_Homo sapiens_hsa05031 | 1.673E-02 | 3.439E-02 | CAMK2A; PRKACA |
| hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 1.768E-02 | 3.537E-02 | CDK6; CDK2 |
| hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 1.534E-02 | 3.339E-02 | TBK1; IKBKE |
| hsa05130 | Pathogenic Escherichia coli infection_Homo sapiens_hsa05130 | 1.149E-02 | 2.743E-02 | ROCK1; ROCK2 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.444E-02 | 3.239E-02 | ALOX15; ALOX12 |
| hsa05340 | Primary immunodeficiency_Homo sapiens_hsa05340 | 5.332E-03 | 1.470E-02 | BTK; JAK3 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 4.259E-03 | 1.261E-02 | POLB; APEX1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.466E-02 | 3.239E-02 | XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| C00-D49: Neoplasms | Polycythemia vera | D45 | JAK2 |
| I00-I99: Diseases of the circulatory system | Peripheral arterial occlusive disease | I73.9 | FGFR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| C00-D49: Neoplasms | Thymoma | C37, D15.0 | CDK2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | CDK2; PDGFRA |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ROCK1; ACHE |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| I00-I99: Diseases of the circulatory system | Peripheral vascular disease | I73.9 | FLT1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | JAK2 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | JAK2 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Renal transplantation | D89.8 | JAK2 |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ROCK1 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | CDK2 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | GSK3A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | FGFR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | GSK3B |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | JAK2 |
| C00-D49: Neoplasms | Myeloproliferative disorder | C94.6 | JAK2 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| NA: NA | Myeloproliferative neoplasm | NA | JAK2 |
| H00-H59: Diseases of the eye and adnexa | Exudative age-related macular degeneration | H35.3 | FLT1 |
| H00-H59: Diseases of the eye and adnexa | Neovascular age-related macular degeneration | H35.3 | FLT1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | CDK2; ROCK1; GSK3B; RET; FGFR1; FLT1; PIM1; ACHE; JAK2; TNK2; PTK2 |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | PDGFRA |
| C00-D49: Neoplasms | Soft tissue sarcoma | C00-D49 | PDGFRA |
| C00-D49: Neoplasms | Endometrial cancer | C54.1 | FGFR1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | FLT1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ROCK1; ACHE |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | PDGFRA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH |
| C00-D49: Neoplasms | Acute promyelocytic leukemia | C92.4 | GSK3A |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | GSK3A |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | ROCK1 |
| C00-D49: Neoplasms | ALK-positive advanced or metastatic NSCLC | C33, C34 | ROS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; ACHE; ACHE; ACHE; MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| I00-I99: Diseases of the circulatory system | Severe coronary heart disease | I25.1 | FGFR1 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | FLT1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2A; ROCK2 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | FLT1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ROCK1 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Renal cancer | C64 | FLT1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2A; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | GSK3A |
| P00-P96: Certain conditions originating in the perinatal period | Central nervous system injury | P11.9 | MAPK10 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| C00-D49: Neoplasms | Ovarian cancer | C56 | PDGFRA |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | FLT1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ROCK1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | IKBKE |
| C00-D49: Neoplasms | Breast cancer | C50 | JAK2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | RET; ACHE; MAPT |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Anemia | D50-D64 | JAK2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ROCK1; PRKCQ |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CDK2; PDGFRA; RET; FGFR1; ROS1; PTK2; MELK |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| C00-D49: Neoplasms | Thyroid cancer | C73 | RET |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | FGFR1 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | FLT1 |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2; MARK3 |
| I00-I99: Diseases of the circulatory system | Hereditary hemorrhagic telangiectasia | I78.0 | FLT1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | JAK2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |